CN101052413B - 特异性组蛋白在治疗寄生虫病中的应用 - Google Patents
特异性组蛋白在治疗寄生虫病中的应用 Download PDFInfo
- Publication number
- CN101052413B CN101052413B CN200480039820.6A CN200480039820A CN101052413B CN 101052413 B CN101052413 B CN 101052413B CN 200480039820 A CN200480039820 A CN 200480039820A CN 101052413 B CN101052413 B CN 101052413B
- Authority
- CN
- China
- Prior art keywords
- histone
- leishmania
- application
- species
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (13)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP03/12421 | 2003-11-05 | ||
EP0312421 | 2003-11-05 | ||
EPPCT/EP2004/001782 | 2004-02-23 | ||
EP2004001782 | 2004-02-23 | ||
PCT/IB2004/004078 WO2005044301A2 (en) | 2003-11-05 | 2004-11-04 | Use of specific histones for the treatment of parasitic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101052413A CN101052413A (zh) | 2007-10-10 |
CN101052413B true CN101052413B (zh) | 2014-05-14 |
Family
ID=34957005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480039820.6A Active CN101052413B (zh) | 2003-11-05 | 2004-11-04 | 特异性组蛋白在治疗寄生虫病中的应用 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1687023B1 (zh) |
JP (2) | JP2007514653A (zh) |
CN (1) | CN101052413B (zh) |
AU (1) | AU2004287284B2 (zh) |
BR (1) | BRPI0416246B8 (zh) |
CY (1) | CY1113621T1 (zh) |
ES (1) | ES2395923T3 (zh) |
IL (1) | IL175412A (zh) |
PT (1) | PT1687023E (zh) |
RS (1) | RS52507B (zh) |
RU (1) | RU2380710C2 (zh) |
WO (1) | WO2005044301A2 (zh) |
ZA (1) | ZA200604053B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4669687B2 (ja) * | 2004-09-27 | 2011-04-13 | 東芝キヤリア株式会社 | マイクロコンピュータのデータ記憶方法 |
FR2883185B1 (fr) * | 2005-03-18 | 2010-11-26 | Pasteur Institut | Composition comprenant la region n-terminale d'histone h2b de leishmania-utilisation pour induire une reponse immunitaire |
RU2558233C2 (ru) | 2009-07-13 | 2015-07-27 | Лабораториос Лети, С.Л. | Диагностика паразитарного заболевания, такого как лейшманиоз, с использованием экстракта рибосомальных белков (rpe) |
SA110310855B1 (ar) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
SG190222A1 (en) | 2010-11-10 | 2013-06-28 | Leti Sl Lab | New adjuvant |
AU2013308623B2 (en) * | 2012-08-30 | 2017-03-02 | Merial, Inc. | Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins |
CN107540735B (zh) * | 2017-10-12 | 2021-11-23 | 中国科学院水生生物研究所 | 一种抗菌蛋白及分离的核酸、抗菌药物和应用 |
EP4348265A2 (en) * | 2021-05-25 | 2024-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnosis of autism spectrum disorder by multiomics platform |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA25182A1 (fr) * | 1996-03-12 | 2001-07-02 | Sovarec Sa | Histones de trypanosomatides, genes et derives de genes les codant, construction d'adn vecteur, organisme hote, tests et vaccins correspondants et leur utilisation |
US6525186B2 (en) * | 1998-12-23 | 2003-02-25 | C.B.F. Leti S.A. | Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained |
-
2004
- 2004-11-04 ES ES04799038T patent/ES2395923T3/es active Active
- 2004-11-04 PT PT47990387T patent/PT1687023E/pt unknown
- 2004-11-04 EP EP04799038A patent/EP1687023B1/en active Active
- 2004-11-04 AU AU2004287284A patent/AU2004287284B2/en active Active
- 2004-11-04 RU RU2006119462/13A patent/RU2380710C2/ru active
- 2004-11-04 BR BRPI0416246A patent/BRPI0416246B8/pt active IP Right Grant
- 2004-11-04 RS RS20120469A patent/RS52507B/en unknown
- 2004-11-04 CN CN200480039820.6A patent/CN101052413B/zh active Active
- 2004-11-04 JP JP2006538999A patent/JP2007514653A/ja not_active Withdrawn
- 2004-11-04 WO PCT/IB2004/004078 patent/WO2005044301A2/en active Application Filing
-
2006
- 2006-05-04 IL IL175412A patent/IL175412A/en active IP Right Grant
- 2006-05-19 ZA ZA2006/04053A patent/ZA200604053B/en unknown
-
2011
- 2011-08-22 JP JP2011180791A patent/JP5623995B2/ja active Active
-
2012
- 2012-11-29 CY CY20121101167T patent/CY1113621T1/el unknown
Non-Patent Citations (4)
Title |
---|
M Soto,et al.Antigenicity of the Leishmania infantum histones H2B and H4during canie viscerocutaneous leishmaniasis.Clinical and Experimental Immunology115 2.1999,115(2),摘要,第346页第2段第9-16行,图3. |
M Soto,et al.Antigenicity of the Leishmania infantum histones H2B and H4during canie viscerocutaneous leishmaniasis.Clinical and Experimental Immunology115 2.1999,115(2),摘要,第346页第2段第9-16行,图3. * |
Melby PC, et al.Identification of vaccine candidates for experimental visceralLeishmaniasis by immunization with sequential fractions of acDNA expression library. Infection and Immunity.Infection and Immunity68 10.2000,68(10),第5600页第3段和表1. |
Melby PC, et al.Identification of vaccine candidates for experimental visceralLeishmaniasis by immunization with sequential fractions of acDNA expression library. Infection and Immunity.Infection and Immunity68 10.2000,68(10),第5600页第3段和表1. * |
Also Published As
Publication number | Publication date |
---|---|
JP2007514653A (ja) | 2007-06-07 |
JP2012051886A (ja) | 2012-03-15 |
RU2006119462A (ru) | 2007-12-20 |
EP1687023A2 (en) | 2006-08-09 |
PT1687023E (pt) | 2013-01-23 |
AU2004287284B2 (en) | 2009-11-12 |
BRPI0416246B1 (pt) | 2019-01-15 |
WO2005044301A2 (en) | 2005-05-19 |
IL175412A (en) | 2012-02-29 |
BRPI0416246B8 (pt) | 2021-05-25 |
ZA200604053B (en) | 2008-04-30 |
JP5623995B2 (ja) | 2014-11-12 |
CN101052413A (zh) | 2007-10-10 |
RS52507B (en) | 2013-04-30 |
WO2005044301A3 (en) | 2005-06-30 |
BRPI0416246A (pt) | 2007-01-09 |
ES2395923T3 (es) | 2013-02-18 |
AU2004287284A1 (en) | 2005-05-19 |
IL175412A0 (en) | 2006-09-05 |
EP1687023B1 (en) | 2012-10-03 |
RU2380710C2 (ru) | 2010-01-27 |
CY1113621T1 (el) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lillehoj et al. | Resistance to intestinal coccidiosis following DNA immunization with the cloned 3-1E Eimeria gene plus IL-2, IL-15, and IFN-γ | |
Stacey et al. | Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major | |
Tighe et al. | Gene vaccination: plasmid DNA is more than just a blueprint | |
Handman et al. | Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response | |
Xu et al. | Vaccination of chickens with DNA vaccine expressing Eimeria tenella MZ5-7 against coccidiosis | |
JP5623995B2 (ja) | 寄生虫疾患の処置のための特異的ヒストンの使用 | |
Gicheru et al. | Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection | |
Iborra et al. | Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice | |
Thirugnanam et al. | Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model | |
Dias et al. | Vaccination with a CD4+ and CD8+ T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis | |
Lage et al. | Prophylactic properties of a Leishmania‐specific hypothetical protein in a murine model of visceral leishmaniasis | |
Shah et al. | The DNA-induced protective immunity with chicken interferon gamma against poultry coccidiosis | |
EP1333840B1 (en) | M. tuberculosis chaperonin 60.1 and uses thereof | |
Ahmad et al. | Sm‐p80‐based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni | |
Fragoso et al. | Heterologous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces protective immunity | |
Carneiro et al. | Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis | |
Barhoumi et al. | Leishmania infantum LeIF and its recombinant polypeptides modulate interleukin IL‐12p70, IL‐10 and tumour necrosis factor‐α production by human monocytes | |
Shi et al. | The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization | |
Soto et al. | Coadministration of the three antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA vaccine induces protection against Leishmania major infection in BALB/c Mice | |
CN102712684A (zh) | L3和/或l5源作为寄生虫病疫苗或诊断的用途 | |
Mahalakshmi et al. | Evaluation of immune response elicited by inulin as an adjuvant with filarial antigens in mice model | |
US9855321B2 (en) | Vaccines against pregnancy-associated malaria | |
ES2546301T3 (es) | Composición que contiene Leishmania Lip2a | |
Christensen et al. | Molecular characterization of a Leishmania donovanii cDNA clone with similarity to human 20S proteasome a-type subunit | |
CN101977930B (zh) | 含核糖体蛋白质提取物(RPE)和任选的促Th1佐剂的疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Applicant Correct: C.B.F.'s private limited company. False: C. B. F. Leti S. L. Unipersonal Number: 41 Page: 783 Volume: 23 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant Correct: C.B.F.'s private limited company. False: C. B. F. Leti S. L. Unipersonal Number: 41 Page: The title page Volume: 23 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: C. B. F. LETI S. L. UNIPERSONAL TO: C.B.F. LEYTI PRIVATE LTD. ^ |
|
ERR | Gazette correction |
Free format text: CORRECT: APPLICANT; FROM: C. B. F. LETI S. L. UNIPERSONAL TO: C.B.F. LEYTI PRIVATE LTD. ^ |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |